Special Issue "Cancer Chemoresistance"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (15 October 2018)
In line with numerous other therapeutic agents, the success of cancer drugs is hindered by the development of clinical drug resistance. The scientific community has mounted a considerable effort in order to understand the underlying mechanisms associated with anticancer drug resistance, over a number of decades. These lines of enquiries have resulted in an enrichment of our knowledge of tumour cell biology—but still leave the oncologist with the day-to-day problem of clinical drug resistance.
Identified molecular pathways that can lead to the development of clinical drug resistance include oncogenic drivers, such as EGFR, PI3K/Akt, disrupted DNA repair, cell death pathways, such as apoptosis and autophagy, the presence of ABC transporters and the process of epithelial-mesenchymal-transition (EMT). Much of this work has been supported by developments in bioinformatics, which make use of open-access databases.
In addition to the issues surrounding the use of cytotoxic drugs associated with standard chemotherapy, new targeted agents such as trastuzumab, lapatinib and gefitinib are also known to be associated with the development of gradual clinical drug resistance. Indeed, some of the mechanisms associated with cytotoxic drugs are shared by some of the targeted cancer therapeutic agents. The overall objective for the cancer scientist is to work hand in hand with the oncologist to find ways to predict in advance clinical drug resistance by the use of biomarker development and also to develop strategies to overcome overt drug resistance for example by the use of combination therapies.Dr. Helen M. Coley
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.